These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32648845)

  • 1. Therapeutic Targets and Computational Approaches on Drug Development for COVID-19.
    Shanmugam A; Muralidharan N; Velmurugan D; Gromiha MM
    Curr Top Med Chem; 2020; 20(24):2210-2220. PubMed ID: 32648845
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19: CADD to the rescue.
    Onawole AT; Sulaiman KO; Kolapo TU; Akinde FO; Adegoke RO
    Virus Res; 2020 Aug; 285():198022. PubMed ID: 32417181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19.
    Tariq A; Mateen RM; Afzal MS; Saleem M
    Int J Infect Dis; 2020 Sep; 98():166-175. PubMed ID: 32579907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
    Choudhary S; Silakari O
    Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.
    Hall DC; Ji HF
    Travel Med Infect Dis; 2020; 35():101646. PubMed ID: 32294562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
    Hage-Melim LIDS; Federico LB; de Oliveira NKS; Francisco VCC; Correia LC; de Lima HB; Gomes SQ; Barcelos MP; Francischini IAG; da Silva CHTP
    Life Sci; 2020 Sep; 256():117963. PubMed ID: 32535080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
    Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
    J Biosci; 2020; 45(1):. PubMed ID: 33184246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances of therapeutic targets and potential drugs of COVID-19.
    Zhang W; Zhang P; Wang G; Cheng W; Chen J; Zhang X
    Pharmazie; 2020 May; 75(5):161-163. PubMed ID: 32393419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
    Robson B
    Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
    Sternberg A; McKee DL; Naujokat C
    Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
    Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
    Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
    Romeo A; Iacovelli F; Falconi M
    Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.